FLUCELVAX® QUADRIVALENT
(Influenza Vaccine)

Coding and Billing


Code for the FLUCELVAX QUADRIVALENT vaccine administered

<table>
<thead>
<tr>
<th>2020-2021 NDC Carton¹</th>
<th>2020-2021 NDC Unit-of-Use¹</th>
<th>Presentation¹</th>
<th>Product Billing CPT Code</th>
<th>Description¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>70461-320-03</td>
<td>70461-320-04</td>
<td>0.5 mL pre-filled syringe</td>
<td>90674</td>
<td>Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>70461-420-10</td>
<td>70461-420-11</td>
<td>5 mL multi-dose vial</td>
<td>90756</td>
<td>Influenza virus vaccine, quadrivalent (ccIV4), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage for intramuscular use</td>
</tr>
</tbody>
</table>

NDC=National Drug Code
Note: Some payers may require use of NDCs. If so, determine if the payer requires the carton NDC or the unit-of-use NDC, and then determine if the payer requires the 10-digit or 11-digit format. If 11-digit, add a leading zero to the middle section of numbers.

Code for the administration of FLUCELVAX QUADRIVALENT

Report the appropriate administration code in addition to the CPT code for FLUCELVAX QUADRIVALENT.²
Note that Medicare (and some other payers) requires use of the Healthcare Common Procedure Coding System (HCPCS) code, G0008, for administration of preventive vaccines, including influenza, regardless of age. Other payers use the appropriate CPT code based on age and counseling provided.³

Include the appropriate International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code

Report the ICD-10 diagnosis code, Z23, indicating an encounter that includes vaccine administration. The ICD-10 diagnosis code should be linked to both the vaccine and the administration codes.³

Determine if modifier 25 is appropriate

When FLUCELVAX QUADRIVALENT is administered on the same date as a significant and separately identifiable Evaluation and Management (E/M) visit, apply modifier 25 to the E/M CPT code, denoting a “significant and separately identifiable” service from the vaccine and vaccine administration service.²

Please see Important Safety Information on next page, and the US full Prescribing Information for FLUCELVAX QUADRIVALENT here.
INDICATION AND USAGE FOR FLUCELVAX® QUADRIVALENT (INFLUENZA VACCINE)

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older.

CONTRAINDICATIONS

• Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine.

WARNINGS & PRECAUTIONS

• Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

ADVERSE REACTIONS

• The most common (≥10%) local and systemic reactions in adults 18–64 years of age were injection site pain (45.4%), headache (18.7%), fatigue (17.8%), myalgia (15.4%), injection site erythema (13.4%), and induration (11.6%).

• The most common (≥10%) local and systemic reactions in adults ≥65 years of age were injection site pain (21.6%) and injection site erythema (11.9%).

• The most common (≥10%) local and systemic reactions in children 4 to <6 years of age were tenderness at the injection site (46%), injection site erythema (18%), sleepiness (19%), irritability (16%), injection site induration (13%), and change in eating habits (10%).

• The most common (≥10%) local and systemic reactions in children 6 through 8 years of age were pain at the injection site (54%), injection site erythema (22%), injection site induration (16%), headache (14%), fatigue (13%), and myalgia (12%).

• The most common (≥10%) local and systemic reactions in children and adolescents 9 through 17 years of age were pain at the injection site (58%), headache (22%), injection site erythema (19%), fatigue (18%), myalgia (16%), and injection site induration (15%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see full Prescribing Information for FLUCELVAX QUADRIVALENT here.

FLUCELVAX QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

Information on reimbursement is provided as a courtesy. Due to the rapidly changing nature of the law, Medicare payment policy, and/or reliance on information provided by outside sources, the information provided herein does not constitute a guarantee or warranty that reimbursement will be received or that the codes identified herein are or will remain applicable. This information is provided “as is” and without any other warranty or guarantee, expressed or implied, as to completeness or accuracy, or otherwise.

Providers must confirm or clarify coding and coverage from their respective payers, and are responsible for accurate reporting of products in accordance with particular payer requirements.


flu360™, FLUCELVAX® QUADRIVALENT, and WE’VE GOT FLU COVERED™ are trademarks of Seqirus UK Limited or its affiliates.

Manufactured by: Seqirus Inc., 475 Green Oaks Parkway, Holly Springs, NC 27540, USA
Distributed by: Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA
©2020 Seqirus USA Inc. July 2020 US/FLU360/0320/0006a